These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 24616310)

  • 1. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
    Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
    J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.
    Ishida T; Joh T; Uike N; Yamamoto K; Utsunomiya A; Yoshida S; Saburi Y; Miyamoto T; Takemoto S; Suzushima H; Tsukasaki K; Nosaka K; Fujiwara H; Ishitsuka K; Inagaki H; Ogura M; Akinaga S; Tomonaga M; Tobinai K; Ueda R
    J Clin Oncol; 2012 Mar; 30(8):837-42. PubMed ID: 22312108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4-positive peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma: A post-marketing surveillance in Japan.
    Ishitsuka K; Yasukawa T; Tsuji Y
    Hematol Oncol; 2024 Jul; 42(4):e3292. PubMed ID: 38847317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
    Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
    J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
    Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
    J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of mogamulizumab and establishment of an optimal therapy based on genomic biomarkers: from the academic viewpoint].
    Iida S; Ishida T; Ueda R
    Yakugaku Zasshi; 2015; 135(5):663-9. PubMed ID: 25948299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
    Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
    Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
    Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
    J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.
    Duvic M; Pinter-Brown LC; Foss FM; Sokol L; Jorgensen JL; Challagundla P; Dwyer KM; Zhang X; Kurman MR; Ballerini R; Liu L; Kim YH
    Blood; 2015 Mar; 125(12):1883-9. PubMed ID: 25605368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.
    Ishida T; Utsunomiya A; Jo T; Yamamoto K; Kato K; Yoshida S; Takemoto S; Suzushima H; Kobayashi Y; Imaizumi Y; Yoshimura K; Kawamura K; Takahashi T; Tobinai K; Ueda R
    Cancer Sci; 2017 Oct; 108(10):2022-2029. PubMed ID: 28776876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.
    Zinzani PL; Karlin L; Radford J; Caballero D; Fields P; Chamuleau ME; d'Amore F; Haioun C; Thieblemont C; González-Barca E; García CG; Johnson PW; van Imhoff GW; Ng T; Dwyer K; Morschhauser F
    Haematologica; 2016 Oct; 101(10):e407-e410. PubMed ID: 27418646
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical Application of Anti-CCR4 Monoclonal Antibody.
    Ueda R
    Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
    Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
    Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
    Kim YH; Bagot M; Pinter-Brown L; Rook AH; Porcu P; Horwitz SM; Whittaker S; Tokura Y; Vermeer M; Zinzani PL; Sokol L; Morris S; Kim EJ; Ortiz-Romero PL; Eradat H; Scarisbrick J; Tsianakas A; Elmets C; Dalle S; Fisher DC; Halwani A; Poligone B; Greer J; Fierro MT; Khot A; Moskowitz AJ; Musiek A; Shustov A; Pro B; Geskin LJ; Dwyer K; Moriya J; Leoni M; Humphrey JS; Hudgens S; Grebennik DO; Tobinai K; Duvic M;
    Lancet Oncol; 2018 Sep; 19(9):1192-1204. PubMed ID: 30100375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies.
    Zhang T; Sun J; Li J; Zhao Y; Zhang T; Yang R; Ma X
    BMC Cancer; 2021 May; 21(1):618. PubMed ID: 34039310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.
    Tobinai K; Takahashi T; Akinaga S
    Curr Hematol Malig Rep; 2012 Sep; 7(3):235-40. PubMed ID: 22538464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
    Sekine M; Kubuki Y; Kameda T; Takeuchi M; Toyama T; Kawano N; Maeda K; Sato S; Ishizaki J; Kawano H; Kamiunten A; Akizuki K; Tahira Y; Shimoda H; Shide K; Hidaka T; Kitanaka A; Yamashita K; Matsuoka H; Shimoda K
    Eur J Haematol; 2017 May; 98(5):501-507. PubMed ID: 28152225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
    Remer M; Al-Shamkhani A; Glennie M; Johnson P
    Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
    Tawa M; Kopp E; McCann S; Cantrell W
    Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
    Winsett FT; Lewis DJ; Duvic M
    Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.